Answers are grounded in this paper and cite their sources.
Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with ⁶⁸Ga or ⁶⁴Cu is currently the gold standard in clinical practice. However, widespread implementation of ⁶⁸Ga imaging is often hampered by practical and economic issues related to ⁶⁸Ge/⁶⁸Ga generators. ¹⁸F offers several advantages to tackle these issues. Recent developments in radiochemistry have allowed a shift from ⁶⁸Ga toward ¹⁸F labeling, leading to promising clinical translations of ¹⁸F-labeled SSAs, such as Gluc-Lys-[¹⁸F]FP-TOCA, [¹⁸F]F-FET-βAG-TOCA, [¹⁸F]AlF-NOTA-octreotide, [¹⁸F]SiTATE, and [¹⁸F]AlF-NOTA-JR11. This review gives an update of currently available clinical data regarding ¹⁸F-labeled SSA tracers and provides justification for the clinical application of this class of tracers.
No takes yet. Share an insight, caveat, or question.
Leupe et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: